GLUE
Monte Rosa Therapeutics Inc
NASDAQ: GLUE · HEALTHCARE · BIOTECHNOLOGY
$20.39
+5.37% today
Updated 2026-05-06
Market cap
$1.50B
P/E ratio
—
P/S ratio
12.16x
EPS (TTM)
$-0.46
Dividend yield
—
52W range
$4 – $26
Volume
1.1M
Monte Rosa Therapeutics Inc (GLUE) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+50.3%
Last 4 quarters
Revenue YoY growth
-95.4%
Most recent quarter
EPS YoY growth
-53.6%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-1.8%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-6.1%
2026-03-12
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-03-12 | $-0.55 | -67.6% | $17.06 | $16.02 | -6.1% |
| 2025-11-06 | $-0.33 | +8.3% | $12.31 | $12.31 | +0.0% |
| 2025-08-07 | $-0.15 | +60.5% | $4.36 | $4.38 | +0.6% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.33 | $-0.55 | -67.6% | $2.78M | -95.4% |
| 2025-09-30 | $-0.36 | $-0.33 | +8.3% | $12.77M | +38.5% |
| 2025-06-30 | $-0.38 | $-0.15 | +60.5% | $23.19M | +394.0% |
| 2025-03-31 | $-0.44 | $0.57 | +229.5% | $84.93M | +7882.0% |
| 2024-12-31 | $0.18 | $-0.36 | -298.9% | $60.65M | +593.0% |
| 2024-09-30 | $-0.47 | $-0.29 | +38.3% | $9.22M | — |
| 2024-06-30 | $-0.52 | $-0.43 | +17.3% | $4.70M | — |
| 2024-03-31 | $-0.57 | $-0.53 | +7.0% | $1.06M | — |
| 2023-12-31 | $-0.33 | $-0.58 | -75.8% | $8.75M | — |
| 2023-09-30 | $-0.72 | $-0.70 | +2.8% | — | — |
| 2023-06-30 | $-0.70 | $-0.71 | -1.4% | — | — |
Frequently asked questions
Has Monte Rosa Therapeutics Inc beaten earnings estimates?
Monte Rosa Therapeutics Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +50.3% over the last 4 quarters.
How does GLUE stock react to earnings?
GLUE stock has moved an average of -1.8% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Monte Rosa Therapeutics Inc's revenue growth rate?
Monte Rosa Therapeutics Inc reported year-over-year revenue growth of -95.4% in its most recent quarter, with EPS growing -53.6% year-over-year.